Accretion Pharmaceuticals Limited (NSE:ACCPL)

India flag India · Delayed Price · Currency is INR
68.65
+3.20 (4.89%)
At close: Mar 10, 2026
-13.10%
Market Cap 763.11M
Revenue (ttm) 826.43M
Net Income (ttm) 90.81M
Shares Out 11.12M
EPS (ttm) 9.82
PE Ratio 6.99
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,200
Average Volume 6,960
Open 66.50
Previous Close 65.45
Day's Range 66.50 - 68.70
52-Week Range 53.80 - 102.50
Beta n/a
RSI 40.97
Earnings Date Feb 13, 2026

About Accretion Pharmaceuticals

Accretion Pharmaceuticals Limited engages in the manufacturing and marketing of pharmaceutical products in India. The company offers antibiotic, antibacterial, antifungal, anti-inflammatory, anti-spasmodic, antihistamine, antiallergy, anticough, anticold, antiulcer, gastrointestinal, antacid, anti-diabetic, cardiac, anti-hypertensive, psychotropic, memory enhancer, vitamins, supplements, and other products. It also provides external preparation, oral powder, effervescent formulation, and nutraceutical products, as well as formulations for brain... [Read more]

Industry Pharmaceutical Preparations
Founded 2012
Employees 125
Stock Exchange National Stock Exchange of India
Ticker Symbol ACCPL
Full Company Profile

Financial Performance

In fiscal year 2025, Accretion Pharmaceuticals's revenue was 573.76 million, an increase of 329.70% compared to the previous year's 133.53 million. Earnings were 67.94 million, an increase of 355.08%.

Financial Statements

News

There is no news available yet.